âª Compatible with XR50R XR70R XR80R XR100R CRF50 CRF50F CRF70 CRF70F CRF80. For Kawasaki KLX110 2011-2016.
âª Compatible with most Chinese 50cc-70cc 110cc 125cc 150cc 4-stroke Pit / Dirt bikes, almost all of the bike brands from China, such as TaoTao, Buyang, Coolsport, Jonway, Extreme, Orion, Znen, NST, BMX, BSE, Kazuma, Sunl, Roketa, AIM-EX etc.
âª All of the original âQAZAKYâ parts are backed by 180 daysâ carefree return, BUY WITH CONFIDENCE!
Please note: 1. some of these bikes may need a little modification by youself, please do check the size carefully before you buy. 2. due to computers display colors differently, the color may vary slightly from the above images.
Specification: 100% brand new and high-quality foot pegs / rests. Color: silver. Weight: 283g. Material: aluminium. With springs pins. Skid proof dampens vibration to improve riding comfort and safty.
Compatible with: For Yamaha BW80 DT50 PW50 PW80 RT100 RT180 dirt bike. For Yamaha T225S TT225T TTR110 TTR50E TTR90 TTR90E TW200 motocross dirt bike. For Yamaha WR200 WR250 WR500 XT250 XT350 XT600 YZ125 YZ250 YZ490 YZ80 dirt bike. For XR50R XR70R XR80R XR100R CRF50 CRF50F CRF70 CRF70F CRF80. For many 50cc 70cc 90cc 110cc 125cc dirt bikes. For Kawasaki KLX110 2011-2016. Fits most Chinese 50cc-70cc 110cc 125cc 150cc 4-stroke Pit / Dirt bikes, almost all of the bike brands from China, such as TaoTao, Buyang, Coolsport, Jonway, Extreme, Orion, Znen, NST, BMX, BSE, Kazuma, Sunl, Roketa, AIM-EX etc.
This open-label, single-arm study investigated the long-term efficacy of tafasitamab plus lenalidomide in 81 patients with relapsed/refractory diffuse large B-cell lymphoma. The response rate was 57.5%, including complete responses in 40.0% of patients, and the median duration of response was 43.9 months. This treatment is a valuable option for patients not eligible for autologous stem-cell transplantation.
Grey zone lymphoma is a B-cell lymphoma, unclassifiable, with features intermediate between those of large B-cell lymphoma and classic Hodgkin lymphoma. The in-depth study of the two adolescent patients described in this case report expands the clinicopathological and genomic spectrum of this rare pediatric disease. Moreover, it provides information on their response to treatment.
The clinical picture of 56 patients with congenital amegakaryocytic thrombocytopenia due to MPL mutations was much more varied than previously thought. Twenty-five per cent of them had no signs of thrombocytopenia at birth, and 50% had non-hematologic defects. Pancytopenia developed in (nearly) all patients and hematopoietic stem-cell transplantation was effective in 87% of cases.
Sickle red blood cells exhibit abnormal adhesion to laminin mediated by Lu/BCAM protein at their surface. This study provides evidence of the involvement of oxidative stress in post-translational modifications of Lu/BCAM which impact the protein’s distribution and cis-interaction with glycophorin C at the cell surface activating its adhesive function in dense sickle red cells. The authors speculate that antioxidant drugs might attenuate this phenomenon.